
|Videos|August 3, 2017
Dr. Rosenberg on Immunotherapy in Non-Metastatic Muscle Invasive Bladder Cancer
Author(s)Jonathan E. Rosenberg, MD
Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses immunotherapy in patients with non-metastatic muscle invasive bladder cancer.
Advertisement
Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses immunotherapy in non-metastatic muscle-invasive bladder cancer.
Immunotherapy for this patient population is in an experimental stage, says Rosenberg.
Ongoing phase III trials are focusing on adjuvant therapy, which Rosenberg says patients who cannot receive platinum-based therapy after surgery should consider.
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5



































